Další formáty:
BibTeX
LaTeX
RIS
@article{1777357,
author = {Riad, Abanoub and Pokorná, Andrea and Mekhemar, Mohamed and Conrad, Jonas and Klugarová, Jitka and Koščík, Michal and Klugar, Miloslav and Attia, Sameh},
article_location = {Basel},
article_number = {6},
doi = {http://dx.doi.org/10.3390/vaccines9060673},
keywords = {AZD1222; ChAdOx1 nCoV-19; COVID-19; Czech Republic; drug-related side effects and adverse reactions; Germany; health personnel; mass vaccination; Oxford–AstraZeneca vaccine},
language = {eng},
issn = {2076-393X},
journal = {Vaccines},
title = {Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States},
url = {https://www.mdpi.com/2076-393X/9/6/673/htm},
volume = {9},
year = {2021}
}
TY - JOUR
ID - 1777357
AU - Riad, Abanoub - Pokorná, Andrea - Mekhemar, Mohamed - Conrad, Jonas - Klugarová, Jitka - Koščík, Michal - Klugar, Miloslav - Attia, Sameh
PY - 2021
TI - Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States
JF - Vaccines
VL - 9
IS - 6
SP - 1-12
EP - 1-12
PB - MDPI
SN - 2076393X
KW - AZD1222
KW - ChAdOx1 nCoV-19
KW - COVID-19
KW - Czech Republic
KW - drug-related side effects and adverse reactions
KW - Germany
KW - health personnel
KW - mass vaccination
KW - Oxford–AstraZeneca vaccine
UR - https://www.mdpi.com/2076-393X/9/6/673/htm
N2 - Recent reports of thrombosis following AstraZeneca COVID-19 vaccine in young females (<55 years-old) led to temporary suspension and urgent investigation by the European Medicines Agency (EMA) that concluded that vaccine benefits still outweigh its side effects (SEs). Therefore, this study aims to provide early independent evidence on the vaccine SEs’ prevalence and their potential risk factors; a cross-sectional survey-based study was carried out between February and March 2021 in Germany and Czech Republic among healthcare workers who recently received the AstraZeneca COVID-19 vaccine. The study used a validated self-administered questionnaire composed of twenty-eight multiple-choice items covering demographic variables, medical anamneses, and local, systemic, oral, and skin related SEs of the vaccine. Out of the ninety-two included participants, 77.2% were females and 79.3% were from Germany. Their mean age was 35.37 ± 12.62 (19–64) years-old, 15.2% had chronic illnesses and 22.8% were receiving medical treatments. Overall, 94.6% of the participants reported at least one SE. The most common local SE was injection site pain (72.8%), and the most common systemic SEs were fatigue (73.9%), muscle pain (55.4%), chills (48.9%), feeling unwell (46.7%), nausea (45.7%), and headache (29.3%). The vast majority (91.9%) resolved within 1–3 days, and the below 35 years-old group was the least affected age group. The SEs’ frequency was insignificantly higher in females and previously infected participants; the vaccine safety for the elderly was supported by the early findings of this study. Chronic illnesses and medical treatments were not associated with an increased risk of SE incidence and frequency. No blood disorder SEs were reported in our sample. Further independent studies are highly required to evaluate the safety of the AstraZeneca vaccine and to explore whether gender or previous infection could be associated with the vaccine SEs.
ER -
RIAD, Abanoub, Andrea POKORNÁ, Mohamed MEKHEMAR, Jonas CONRAD, Jitka KLUGAROVÁ, Michal KOŠČÍK, Miloslav KLUGAR a Sameh ATTIA. Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States. \textit{Vaccines}. Basel: MDPI, 2021, roč.~9, č.~6, s.~1-12. ISSN~2076-393X. Dostupné z: https://dx.doi.org/10.3390/vaccines9060673.
|
